“Our Mission: Developing Superior Protection from Pulmonary
  Embolisms”

Crux Biomedical, Inc., was formed in August 2004 by
physicians Tom Fogarty and Frank Arko based upon their
observations of the clinical limitations of current vena
cava filters. Dr. Fogarty subsequently formed an Advisory Board of nationally respected endovascular specialists to develop a revolutionary retrievable vena cava filter .

By December of 2004, the company filed its first provisional
patents and subsequently filed 7 U.S. patents and
1 international patent.

In July of 2005, the Company raised its Series A Preferred equity of $3.8MM to support device prototyping, in vitro bench testing and animal studies. The success of these activities resulted in both the initiation of successful human implants outside the United States in January of 2006 and the filing of an Investigational Device Exemption (IDE) with the FDA in early 2007. This filing and subsequent conditional approval by the FDA in September, 2007 permitted the start of the Company’s RETRIEVE Clinical Evaluation.

The Crux IVC Filter will be clinically evaluated at 12 centers of excellence around the United States. The RETRIEVE study is anticipated to conclude in mid-2008. A second round of private funding was secured in September of 2007 to provide resources for the U.S. clinical trials and expansion of current operations at its Menlo Park manufacturing facility.

Under the guidance of Drs. Fogarty and Arko and the Company’s Scientific Advisory Board, Crux believes it can address some of the limitations of current VCF with its revolutionary design.

Crux announces successful implantation and retrieval at the French Hospital (Asuncion, Paraguay) with Dr. Adrian Ebner and Dr. Frank Arko, co-founder of Crux and Chief of Endovascular Surgery at University of Texas Southwestern.